Education
About Us
Working with TipRanks
Follow Us
Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
RESEARCH TOOLSreports
Total Valuation
Allergy Therapeutics has a market cap or net worth of £345.57M. The enterprise value is ―.
Market Cap£345.57M
Enterprise Value―
Share Statistics
Allergy Therapeutics has 4,766,440,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,766,440,000
Owned by Insiders―
Owned by Institutions0.12%
Financial Efficiency
Allergy Therapeutics’s return on equity (ROE) is -10.84 and return on invested capital (ROIC) is -78.03%.
Return on Equity (ROE)-10.84
Return on Assets (ROA)-0.62
Return on Invested Capital (ROIC)-78.03%
Return on Capital Employed (ROCE)-0.80
Revenue Per Employee90.19K
Profits Per Employee-65.71K
Employee Count612
Asset Turnover0.85
Inventory Turnover2.00
Valuation Ratios
The current PE Ratio of Allergy Therapeutics is -4.37. Allergy Therapeutics’s PEG ratio is -0.35.
PE Ratio-4.37
PS Ratio0.00
PB Ratio-49.00
Price to Fair Value47.44
Price to FCF-10.77
Price to Operating Cash Flow-11.88
PEG Ratio-0.35
Income Statement
In the last 12 months, Allergy Therapeutics had revenue of 55.20M and earned -40.22M in profits. Earnings per share was -0.01.
Revenue55.20M
Gross Profit29.74M
Operating Income-35.26M
Pretax Income-39.17M
Net Income-40.22M
EBITDA-30.74M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -29.48M and capital expenditures -3.06M, giving a free cash flow of -32.54M billion.
Operating Cash Flow-29.48M
Free Cash Flow-32.54M
Free Cash Flow per Share>-0.01
Dividends & Yields
Allergy Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.90
52-Week Price Change113.24%
50-Day Moving Average6.53
200-Day Moving Average5.82
Relative Strength Index (RSI)62.05
Average Volume (3m)458.71K
Important Dates
Allergy Therapeutics upcoming earnings date is Sep 24, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateSep 24, 2025
Ex-Dividend Date―
Financial Position
Allergy Therapeutics as a current ratio of 1.63, with Debt / Equity ratio of -622.64%
Current Ratio1.63
Quick Ratio1.01
Debt to Market Cap0.13
Net Debt to EBITDA-0.59
Interest Coverage Ratio-8.58
Taxes
In the past 12 months, Allergy Therapeutics has paid 1.05M in taxes.
Income Tax1.05M
Effective Tax Rate-0.03
Enterprise Valuation
Allergy Therapeutics EV to EBITDA ratio is -6.31, with an EV/FCF ratio of -5.46.
EV to Sales3.51
EV to EBITDA-6.31
EV to Free Cash Flow-5.46
EV to Operating Cash Flow-6.04
Balance Sheet
Allergy Therapeutics has £21.68M in cash and marketable securities with £44.52M in debt, giving a net cash position of £22.84M billion.
Cash & Marketable Securities£21.68M
Total Debt£44.52M
Net Cash£22.84M
Net Cash Per Share<£0.01
Tangible Book Value Per Share>-£0.01
Margins
Gross margin is 54.04%, with operating margin of -63.87%, and net profit margin of -72.86%.
Gross Margin54.04%
Operating Margin-63.87%
Pretax Margin-70.95%
Net Profit Margin-72.86%
EBITDA Margin-55.69%
EBIT Margin-63.51%
Analyst Forecast
The average price target for Allergy Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast4.50%
EPS Growth Forecast74.32%